Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.

In Arm A, differential abundance analysis of the phenograph -defined clusters showed no statistically significant differences between non-progressors (best response of PR or SD for ≥3 months) and progressors (best response of progressive disease or SD for <3 months) ( figure 4A ), although non-progressors showed a trend toward a higher proportion of cluster 3 ɣδ T cells ( figure 4B ).

also in 53,322 other papers